Kling Biotherapeutics Showcases Innovative Antibody Technologies
Kling Biotherapeutics, a biotech trailblazer known for its cutting-edge work in antibody-based drug development, is set to unveil its latest platforms at the Annual Protein & Antibody Engineering Summit (PEGS) Europe, in a crucial event for the biopharmaceutical industry.
The Kling-Select Platform: Building A Bridge to Novel Therapeutics
At the heart of Klings' presentation is Kling-Select, a revolutionary approach that promises to broaden the horizons for identifying therapeutic antibodies and novel targets. This technology harnesses B cells from a variety of sources, including human and animal specimens, such as camels and rabbits. The speed and efficiency of the process are remarkable, allowing for the discovery of functional monoclonal antibodies from primary B cells in under three weeks.
Kling-Select in Action
With its capabilities, Kling-Select has been instrumental in identifying crucial therapeutic targets that can potentially transform treatment approaches for a range of diseases. The platform's ability to capture and immortalize circulating and tissue-infiltrating B cell repertoires ensures that the most valuable immune responses are considered in the therapeutic development process.
Kling-Evolve: A Rapid Response Mechanism
Alongside Kling-Select, Kling-Evolve is designed to tackle the ever-evolving landscape of infectious diseases. This platform is particularly significant when considering the emergence of viral escape variants, as it allows rapid ex vivo maturation of B cells. By utilizing Kling-Evolve, researchers can identify neutralizing antibodies specifically targeted against these evolving threats.
The Need for Speed in Antibody Development
In an era marked by various pandemic threats, the importance of rapid antibody development cannot be overstated. Kling-Evolve stands ready to respond to outbreaks swiftly, providing essential countermeasures that will play a crucial role in pandemic preparedness.
Expert Insights from Kling Biotherapeutics
Michael Koslowski, CEO of Kling Biotherapeutics, asserted the clinical validation of their platforms, referencing their successful discovery of the Respiratory Syncytial Virus (RSV) neutralizing antibody, nirsevimab (Beyfortus™) developed in collaboration with AstraZeneca and Sanofi. Koslowski’s remarks illuminate the company’s commitment to effectively addressing current global health challenges through innovative technology.
Presentation Highlights and Key Sessions
The upcoming poster sessions are key moments of the PEGS Europe event, featuring:
- Poster Title: Highly efficient capture of circulating and tissue-infiltrating B cell repertoires from multiple species: Kling-Select
- Presenter: Casper Marsman, Senior Scientist – B Cell Platform Lead, Kling Biotherapeutics
- Presentation Number: A073
- Poster Title: Kling-Evolve as a tool for rapid response to emerging variants and pandemic preparedness: directed evolution of variant-specific antibody from immortalized B cells
- Presenter: Alessandra Villa, Director of Discovery Platforms, Kling Biotherapeutics
- Presentation Number: A074
Attendees can look forward to more detailed discussions on these technologies during the exhibition hall showcases scheduled over several days.
About Kling Biotherapeutics
Kling Biotherapeutics is dedicated to pushing the boundaries of antibody discovery and therapeutic development. With its base in Amsterdam, the company boasts a robust portfolio of specific intellectual property encompassing its groundbreaking platforms, Kling-Select and Kling-Evolve.
This innovative approach not only enhances the identification of therapeutic targets but also addresses the growing need for effective treatment options in oncology and infectious diseases. Their ongoing research includes KBA1412, a pioneering CD9 antibody currently under exploration for blood cancer therapies.
The Significance of PEGS Europe
PEGS Europe stands out as the premier event in the protein and antibody engineering landscape, showcasing advancements in biologics technology. This year’s conference has expanded its focus to cover artificial intelligence, multispecific antibodies, and antibody-drug conjugates, reflecting the evolution of the field in line with emerging scientific frontiers.
Frequently Asked Questions
What are the main platforms presented by Kling Biotherapeutics?
Kling Biotherapeutics presents two main platforms: Kling-Select for antibody discovery and Kling-Evolve for rapid response to emerging variants.
Why is Kling-Select significant?
Kling-Select efficiently captures B cells from various sources, facilitating the discovery of therapeutic antibodies in record time.
How does Kling-Evolve contribute to pandemic preparedness?
Kling-Evolve enables rapid maturation of antibodies to counter emerging viral variants, crucial for managing future pandemics.
What notable success has Kling achieved with its technology?
The company successfully developed nirsevimab (Beyfortus™), a neutralizing antibody for RSV, showcasing its clinical capabilities.
Where is Kling Biotherapeutics headquartered?
Kling Biotherapeutics is headquartered in Amsterdam, focusing on antibody discovery and therapeutic development.
